## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.1% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (57% of avg), momentum weakening (-18.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($102.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-18.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.1B |
| Beta | -0.11 |
| 52W Range | $4.77 - $138.49 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 17.9% to -0.1% (-18.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. Volume at 57% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.15% (CS: 58) | Neutral |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | -0.22 | Bearish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.154x | Above |
| vs SMA200 | 2.547x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $114.83
- **Stop Loss:** $102.61 (10.6% risk)
- **Target:** $127.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $9,301.23
- **Portfolio %:** 9.30%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*